Advancing chronic obstructive pulmonary disease management: The case for multi-biomarker precision medicine-A narrative review.
Authors
Affiliations (2)
Affiliations (2)
- Department of Pharmacy Practice, SRM College of Pharmacy, Faculty of Medicine and Health Sciences, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu, Tamil Nadu, India.
- Department of Respiratory Medicine, SRM Medical College Hospital, Faculty of Medicine and Health Sciences, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu, Tamil Nadu, India.
Abstract
Chronic obstructive pulmonary disease (COPD) is increasingly recognized as a biologically heterogeneous disorder that extends beyond eosinophilic inflammation alone. Although blood eosinophil counts are clinically useful for guiding inhaled corticosteroid therapy, they represent only a single inflammatory endotype and fail to capture the full spectrum of disease mechanisms that influence progression, exacerbations, and treatment response. This narrative review synthesizes emerging evidence supporting a multidomain, multi-biomarker framework for COPD phenotyping that integrates systemic inflammatory markers, epithelial injury proteins, structural imaging parameters, and environmental or exposomic indicators. Studies published between January 2010 and September 2024 demonstrate that combined assessment of biomarkers such as C-reactive protein, interleukin-6, fibrinogen, surfactant protein-D, club cell secretory protein-16, quantitative computed tomography metrics, and selected exposomic measures improves prediction of exacerbations and mortality compared with eosinophil-guided strategies alone. Advanced approaches that incorporate artificial intelligence and multi-omics data further enhance phenotype identification in research and early translational settings, although routine clinical implementation remains limited by cost, standardization, and feasibility. Overall, movement toward a multi-biomarker precision-medicine paradigm has the potential to refine therapeutic decision-making, reduce inappropriate corticosteroid exposure, and support more equitable, data-driven COPD management. However, successful translation will require robust validation, standardized assays, cost-effective diagnostic platforms, and integration into digital clinical workflows, particularly in low- and middle-income healthcare settings.